Evaluation Liverghol Impact on Liver Enzymes

Study of Oral Liverghol Impact on Liver Enzymes in Patients with Thalassemia Major and Intermedia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150119020715N9

Enrollment

Registered

2019-01-17

Start date

2018-09-22

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thalassemia Major and Intermedia. Thalassemia

Interventions

Intervention 1: Intervention group: In cases under 12 years of age take 70 mg and over 12 years of age take 140 mg of Liverghol oral pills two times per day, for 6 months. Intervention 2: Control grou

Eligibility

Sex/Gender

All

Age

5 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients over 5 years of age with ß-thalassemia Major and Intermedia referring to Amir Kabir hospital in Arak Informed consent of the participants in the study Disrupted liver enzymes (AST and ALT greater than 60). Total cholesterol above 200 Total bilirubin equal to or greater than 2 GGT more than 60

Exclusion criteria

Exclusion criteria: With other blood diseases and liver diseases such as HBV, HCV and HIV

Design outcomes

Primary

Measure	Time frame
Liver Enzymes. Timepoint: Before treatment, with a month's interval in six month from starting treatment. Method of measurement: Blood tests.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAziz Eghbali

Arak University of Medical Sciences

dr.eghbali@arakmu.ac.ir+33 135075

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026